Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar;57(3):1262-71.
doi: 10.1002/hep.26179.

Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection

Stephen J Polyak  1 , Peter Ferenci, Jean-Michel Pawlotsky
Affiliations
Review

Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection

Stephen J Polyak et al. Hepatology. 2013 Mar.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Structural basics of silymarin
Left panel shows the basic structure of a flavonoid. The two benzene rings are designated A and B, while the 3 carbon chain forms ring C. The wavy line that links ring C to ring B indicates the many flavonoids are actually racemic mixtures because the carbon at position 2 on ring C (C2) can be chiral provided there is a single bond between C2 and C3. If there is a double bond between C2 and C3, the flavonoid is not chiral. Right panel shows how Taxifolin (a chiral flavonoid) and coniferyl alcohol condense to form silybin A. The blue color-coding shows how conferyl alcohol is incorporated into the larger flavonolignan molecule.
Figure 2
Figure 2. Structures and nomenclature of compounds found in silymarin
Please refer to text for details.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. NCCAM. Research Report: National Center for Complementary and Alternative Medicine. 2003. Hepatitis C and Complementary and Alternative Medicine: 2003 Update; pp. 2–20.
    1. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008;47:605–612. - PubMed
    1. Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol. 2002;97:2391–2397. - PubMed
    1. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology. 2007;132:1925–1936. - PubMed
    1. Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, Sinha R, Everhart JE the HALT-C Trial Group. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2010 2 NOV 2010. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources